Health Reference Series: Drug Abuse Sourcebook

Editor/Author Williams, Angela
Publication Year: 2019
Publisher: Omnigraphics, Inc.

Single-User Purchase Price: $95.00
Unlimited-User Purchase Price: $142.50
ISBN: 978-0-7808-1683-1
Category: Health & Medicine - Health
Image Count: 50
Book Status: Available
Table of Contents

Drug Abuse Sourcebook, Sixth Edition, provides updated information about the abuse of illegal drugs and the misuse of prescription and over-the-counter medications.

Share this

Table of Contents

  • Preface
  • Part I: Facts and Statistics about Drug Abuse in the United States
  • Chapter 1—Prevalence of Drug Abuse in the United States
  • Chapter 2—Drugs: Abuse and Addiction
  • Section 2.1—What Is Drug Abuse?
  • Section 2.2—What Is Drug Addiction?
  • Chapter 3—How Drugs Impact Brain
  • Chapter 4—Genetics and Epigenetics of Addiction
  • Chapter 5—Drug Abuse and Related Hospitalization Costs
  • Section 5.1—Substance Abuse Cost to Society
  • Section 5.2—Drug-Related Hospital Emergency Room Visits
  • Section 5.3—Increase in Emergency Room Visits Related to Ecstasy
  • Section 5.4—Deaths from Drug Overdoses
  • Chapter 6—Understanding the Legal Use of Controlled Substances
  • Section 6.1—Prescriptions for Controlled Substances
  • Section 6.2—Is Marijuana Medicine?
  • Chapter 7—Regulations Regarding Controlled Substances
  • Section 7.1—The Controlled Substances Act and the Schedule Classifications
  • Section 7.2—Combat Methamphetamine Epidemic Act
  • Chapter 8—Drugs—Shatter the Myths
  • Chapter 9—Substance-Abuse Treatment Statistics
  • Part II: Drug Abuse and Specific Populations
  • Chapter 10—Adolescent Drug Abuse
  • Section 10.1—Trends in Adolescent Drug Abuse
  • Section 10.2—Reasons Adolescents Try Drugs and Alcohol
  • Section 10.3—Adolescents and Prescription-Drug Misuse
  • Section 10.4—Adolescent Marijuana Use
  • Section 10.5—Adolescents and Opioids
  • Section 10.6—School Dropouts and Substance Abuse
  • Chapter 11—Drug Use among College Students
  • Chapter 12—Substance-Abuse Issues of Concern to Women
  • Section 12.1—Alcohol-Use Disorder,Substance-Use Disorder,and Addiction among Women
  • Section 12.2—Substance Use While Pregnant and Breastfeeding
  • Section 12.3—Negative Consequences of Prenatal Exposure to Drugs
  • Section 12.4—What Women Need to Know about Date Rape Drugs
  • Chapter 13—Cigarette Smoking and Tobacco Use among People of Low Socioeconomic Status
  • Chapter 14—Substance Abuse in the Workplace
  • Chapter 15—Seniors and Drug Abuse
  • Chapter 16—Substance Abuse in the LGBT Community
  • Chapter 17—Substance Abuse in the Racial and Ethnic Minority Populations
  • Chapter 18—Drug Abuse in Other Populations
  • Section 18.1—Veterans and Drug Abuse
  • Section 18.2—Criminal Justice Populations and Substance Abuse
  • Section 18.3—Substance-Use Disorders in People with Disabilities
  • Part III: Drugs of Abuse
  • Chapter 19—Introduction to Drug Classes
  • Chapter 20—Anabolic Steroids and Related Drugs Used as Performance Enhancers
  • Section 20.1—Anabolic Steroids
  • Section 20.2—Clenbuterol
  • Section 20.3—Human Growth Hormone (hGH)
  • Chapter 21—Cannabinoids
  • Section 21.1—Cannabis and Cannabinoids
  • Section 21.2—Synthetic Cannabinoids (K2/Spice)
  • Chapter 22—Club Drugs
  • Section 22.1—What Are Club Drugs?
  • Section 22.2—Gamma-Hydroxybutyrate (GHB)
  • Section 22.3—Ketamine
  • Section 22.4—Rohypnol
  • Chapter 23—Dissociative Drugs
  • Section 23.1—Dextromethorphan (DXM)
  • Section 23.2—Phencyclidine (PCP)
  • Section 23.3—Salvia divinorum
  • Chapter 24—Hallucinogenic Drugs
  • Section 24.1—Introduction to Hallucinogens
  • Section 24.2—4-Iodo-2,5-Dimethoxyphenethylamine
  • Section 24.3—Alpha-Methyltryptamine (Spirals)
  • Section 24.4—Blue Mystic (2C-T-7)
  • Section 24.5—DMT
  • Section 24.6—Ecstasy (MDMA)
  • Section 24.7—Foxy
  • Section 24.8—LSD
  • Section 24.9—Mescaline (Peyote)
  • Section 24.10—Psilocybin
  • Section 24.11—Toonies (Nexus, 2C-B)
  • Chapter 25—Inhalants
  • Chapter 26—Narcotics (Opioids)
  • Section 26.1—Introduction to Narcotics
  • Section 26.2—Buprenorphine
  • Section 26.3—Fentanyl
  • Section 26.4—Heroin
  • Section 26.5—Hydrocodone
  • Section 26.6—Hydromorphone
  • Section 26.7—Methadone
  • Section 26.8—Oxycodone
  • Chapter 27—Sedatives (Depressants)
  • Section 27.1—Introduction to Depressants
  • Section 27.2—Barbiturates
  • Section 27.3—Benzodiazepines
  • Section 27.4—Kava
  • Chapter 28—Stimulants
  • Section 28.1—Introduction to Stimulants
  • Section 28.2—Amphetamine
  • Section 28.3—BZP
  • Section 28.4—Cocaine
  • Section 28.5—Khat
  • Section 28.6—Kratom
  • Section 28.7—Methamphetamine
  • Section 28.8—Methylphenidate
  • Chapter 29—Synthetic Drugs
  • Section 29.1—What Are Synthetic Drugs?
  • Section 29.2—Bath Salts
  • Chapter 30—Tobacco, Nicotine, and E-Cigarettes
  • Part IV: The Causes and Consequences of Drug Abuse and Addiction
  • Chapter 31—Drug Addiction Is a Chronic Disease
  • Chapter 32—Common Risk and Protective Factors for Drug Use
  • Chapter 33—Prescription and Over-the-Counter Drug Abuse
  • Section 33.1—Causes and Prevalence of Prescription-Drug Misuse
  • Section 33.2—Over-the-Counter Medicines and Their Misuse
  • Section 33.3—Misuse of Over-the-Counter Cough and Cold Medicines
  • Chapter 34—Legal, Financial, and Social Consequences of Drug Abuse
  • Section 34.1—Legal Consequences of Drug Abuse
  • Section 34.2—Financial Consequences of Drug Abuse
  • Section 34.3—Drugged Driving
  • Chapter 35—Health Consequences of Drug Addiction
  • Section 35.1—Poor Health Outcomes of Commonly Abused Drugs
  • Section 35.2—Substance Abuse and Medical Complications
  • Section 35.3—Marijuana's Long-Term Effects on the Brain
  • Section 35.4—Opioid Overdose
  • Chapter 36—Preventing Disease in Drug-Abusing Populations
  • Section 36.1—Drug Abuse and Infectious Diseases
  • Section 36.2—The Connection between HIV/AIDS and Drug Abuse
  • Section 36.3—Hepatitis Infection and Drug Use
  • Section 36.4—Sterile Syringe Programs
  • Chapter 37—Mental Illness and Addiction
  • Section 37.1—Addiction and Mental-Health Disorders
  • Section 37.2—Depression and Initiation of Alcohol and Drug Abuse in Teens
  • Chapter 38—Substance Abuse and Suicide Prevention
  • Part V: Drug-Abuse Treatment and Recovery
  • Chapter 39—Recognizing Drug Use
  • Section 39.1—Signs of Drug Use
  • Section 39.2—Am I Drug Addicted?
  • Section 39.3—How to Identify Drug Paraphernalia
  • Chapter 40—Drug-Abuse Intervention
  • Chapter 41—Drug-Abuse Treatment in a Healthcare Setting
  • Section 41.1—Medical Professionals Need to Identify Substance-Use Disorders
  • Section 41.2—Addiction Treatment Neglected in the Healthcare Setting
  • Chapter 42—Detoxification
  • Chapter 43—Treatment for Drug Addiction: An Overview
  • Chapter 44—Medication and Counseling Treatment
  • Section 44.1—What Is Medication and Counseling Treatment?
  • Section 44.2—Medication and Counseling Treatment—Buprenorphine
  • Section 44.3—Medication and Counseling Treatment—Methadone
  • Section 44.4—Medication and Counseling Treatment—Naltrexone
  • Section 44.5—Medication and Counseling Treatment—Naloxone
  • Section 44.6—Medication and Counseling Treatment—Opioid Overdose
  • Chapter 45—Treatment for Methamphetamine Addiction
  • Chapter 46—Supporting Substance-Abuse Recovery
  • Section 46.1—What Is Recovery?
  • Section 46.2—Recovery Support Services
  • Chapter 47—Know Your Rights: Parity for Mental-Health and Substance-Use Disorder Benefits
  • Chapter 48—Employee-Assistance Programs for Substance Abuse
  • Chapter 49—Drug Courts
  • Part VI: Drug-Abuse Testing and Prevention
  • Chapter 50—Drug-Abuse Prevention Begins at Home
  • Section 50.1—Talking to Your Child about Tobacco, Alcohol,and Drugs
  • Section 50.2—What to Do If Your Teen or Young Adult Has a Problem with Drugs
  • Section 50.3—How to Minimize Prescription-Drug Misuse and Abuse among Teens
  • Section 50.4—Tips for Parents: The Truth about Club Drugs
  • Chapter 51—Drug-Abuse Testing and Prevention in Schools
  • Section 51.1—Drug Testing in Schools
  • Section 51.2—Drug-Use Prevention Education in Schools
  • Chapter 52—Drug Testing
  • Section 52.1—Drug Testing
  • Section 52.2—Home-Use Drug Testing
  • Chapter 53—Preventing Drug Abuse in the Workplace
  • Section 53.1—Drug-Free Workplace Policies
  • Section 53.2—Drug Testing in the Workplace
  • Chapter 54—Substance-Misuse-Prevention Media Campaigns
  • Part VII: Additional Help and Information
  • Chapter 55—Glossary of Terms Related to Drug Abuse
  • Chapter 56—Glossary of Street Terms for Drugs of Abuse
  • Chapter 57—Directory of State Substance-Abuse Agencies
  • Chapter 58—Directory of Organizations Providing Information about Drug Abuse